Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exemestane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exemestane SCHEMBL172893 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL2233503 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL19452231 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6730580 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL13794245 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6215 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL1781618 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172860 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL21698489 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| SCHEMBL13301017 | 0.92 | CYP19A1 (0.84) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2042 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-12043667-B2 | CLEC12a binding polypeptides and uses thereof | INHIBRX BIOSCIENCES, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023178290-A9 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12037385-B2 | Anti-polyubiquitin antibodies and methods of use | GENENTECH, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228664-A9 | Antibodies Binding to Human PAD4 and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228653-A1 | PSGL-1 Antagonists and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226082-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TESARO, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12030926-B2 | Production of heteromultimeric proteins using mammalian cells | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2005033132-A2 | IGF BINDING PROTEINS | GENENTECH, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050037431-A1 | Methods and compositions for modulating HGF/Met | GENENTECH, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005012359-A2 | ANTI-VEGF ANTIBODIES | GENENTECH, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005002582-A2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003154-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005001486-A1 | MODULATING THE INTERACTION BETWEEN HGF BETA CHAIN AND C-MET | GENENTECH, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1401476-A2 | IGF ANTAGONIST PEPTIDES | Genentech, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030092631-A1 | IGF antagonist peptides | GENENTECH, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072780-A2 | IGF ANTAGONIST PEPTIDES | GENENTECH, INC. (US) | 2002-09-19 | — | — | WO | disclosed |